The United States' recent approval of a new drug to treat type 2 diabetes has paved the way
for its introduction in Canada. The US Food and Drug Administration (FDA) approved …

Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2)
inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen …

Introduction: Inhibition of the sodium-glucose cotransporter 2 (SGLT2), to promote the
excretion of glucose, is a new paradigm in the treatment of type 2 diabetes. Areas covered …

Abstract The US Food and Drug Administration have approved (on March 29, 2013) a novel
glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the …

Canagliflozin (INVOKANA), dapagliflozin (FARXIGA) and empagliflozin (JARDIANCE)
belong to the newest class of drugs approved for the treatment of Type 2 diabetes.[1] These …

Toronto, ON (May 26, 2014)—Janssen Inc. announced today that Health Canada has
approved INVOKANA™(canagliflozin), an oral, once-daily prescription treatment used to …

Canagliflozin is a sodium‐glucose transporter protein inhibitor under development for the
treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary …

Purpose The published evidence on the pharmacology, pharmacodynamics,
pharmacokinetics, safety, and efficacy of a promising investigational agent for managing …

Canagliflozin is a newly approved sodium-glucose cotransporter 2 inhibitor for Type 2
diabetes. It is used along with diet and exercise in patients who are intolerant to metformin …